A single institutional experience of surgically resected thymic epithelial tumors over 10 years - Clinical outcomes and clinicopathologic features

Beom Kyung Kim, ByoungChul Cho, Hye Jin Choi, Joo Hyuk Sohn, Moo Suk Park, Joon Chang, Se Kyu Kim, Dae Joon Kim, Kyung Young Chung, Chang Geol Lee, Joo Hang Kim, Nae Choon Yoo

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Thymic epithelial tumors (TETs) consist of a series of neoplasm that differ morphologically and biologically. Due to its rarity and indolent natural history, large-scale prospective trials have been lacking. This study aimed to evaluate long-term clinical outcomes and clinicopathologic features for TET after surgical resection and adjuvant treatments. One hundred patients who received surgery plus adjuvant radiotherapy ± chemotherapy for TET (Masaoka stage II-IVa) from 1995 to 2005 were retrospectively reviewed. Masaoka staging systems were adopted, and pathologic results were classified according to World health organization (WHO) histologic classification. After surgery, 55 patients were treated with radiotherapy alone, while 45 with radiotherapy and chemotherapy. The median radiation dose was 50.4 Gy (45-63 Gy) and six cycles of chemotherapy, consisting of doxorubicin, cisplatin, vincristine and cyclophosphamide, were applied every 3-4 weeks. Distributions according to Masaoka stage were as follows; stage II (58 patients), III (21) and IVa (21). According to WHO histology, there were A (3), AB (7), B1 (7), B2 (31), B3 (31) and C (21). With a median follow-up duration of 65 months (8-143 months), the 5-year overall survival (OS) and disease-free survival (DFS) rates were 75.7% (89.2, 67.9 and 52.1% in stage II, III and IVa, respectively) and 70.3% (83, 62.4 and 33.6% in stage II, III and IVa, respectively). In multivariate analysis, prognostic factors for OS were age, WHO histology, Masaoka stage, and recurrence, while pleural involvement, WHO histology, and Masaoka stage had significant impacts on DFS. Adjuvant chemotherapy did not alter survival outcomes and recurrence patterns. Pleura was the most common recurrence site (15 patients, 53.6%), and significantly associated with pleural recurrence-free survival. In conclusion, pleural involvement at diagnosis was the important prognostic factor, in addition to WHO histology and Masaoka stage. To prevent pleural recurrence and prolong survival, innovative therapeutic approaches warrant further investigations.

Original languageEnglish
Pages (from-to)1525-1531
Number of pages7
JournalOncology Reports
Volume19
Issue number6
Publication statusPublished - 2008 Jun 1

Fingerprint

Histology
Recurrence
Survival
Adjuvant Chemotherapy
Disease-Free Survival
Radiotherapy
Drug Therapy
Adjuvant Radiotherapy
Pleura
Vincristine
Natural History
Doxorubicin
Cyclophosphamide
Cisplatin
Multivariate Analysis
Survival Rate
Thymic epithelial tumor
Radiation
Therapeutics
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Kim, Beom Kyung ; Cho, ByoungChul ; Choi, Hye Jin ; Sohn, Joo Hyuk ; Park, Moo Suk ; Chang, Joon ; Kim, Se Kyu ; Kim, Dae Joon ; Chung, Kyung Young ; Lee, Chang Geol ; Kim, Joo Hang ; Yoo, Nae Choon. / A single institutional experience of surgically resected thymic epithelial tumors over 10 years - Clinical outcomes and clinicopathologic features. In: Oncology Reports. 2008 ; Vol. 19, No. 6. pp. 1525-1531.
@article{72ffa4730c004b7b94894c678e1f9f54,
title = "A single institutional experience of surgically resected thymic epithelial tumors over 10 years - Clinical outcomes and clinicopathologic features",
abstract = "Thymic epithelial tumors (TETs) consist of a series of neoplasm that differ morphologically and biologically. Due to its rarity and indolent natural history, large-scale prospective trials have been lacking. This study aimed to evaluate long-term clinical outcomes and clinicopathologic features for TET after surgical resection and adjuvant treatments. One hundred patients who received surgery plus adjuvant radiotherapy ± chemotherapy for TET (Masaoka stage II-IVa) from 1995 to 2005 were retrospectively reviewed. Masaoka staging systems were adopted, and pathologic results were classified according to World health organization (WHO) histologic classification. After surgery, 55 patients were treated with radiotherapy alone, while 45 with radiotherapy and chemotherapy. The median radiation dose was 50.4 Gy (45-63 Gy) and six cycles of chemotherapy, consisting of doxorubicin, cisplatin, vincristine and cyclophosphamide, were applied every 3-4 weeks. Distributions according to Masaoka stage were as follows; stage II (58 patients), III (21) and IVa (21). According to WHO histology, there were A (3), AB (7), B1 (7), B2 (31), B3 (31) and C (21). With a median follow-up duration of 65 months (8-143 months), the 5-year overall survival (OS) and disease-free survival (DFS) rates were 75.7{\%} (89.2, 67.9 and 52.1{\%} in stage II, III and IVa, respectively) and 70.3{\%} (83, 62.4 and 33.6{\%} in stage II, III and IVa, respectively). In multivariate analysis, prognostic factors for OS were age, WHO histology, Masaoka stage, and recurrence, while pleural involvement, WHO histology, and Masaoka stage had significant impacts on DFS. Adjuvant chemotherapy did not alter survival outcomes and recurrence patterns. Pleura was the most common recurrence site (15 patients, 53.6{\%}), and significantly associated with pleural recurrence-free survival. In conclusion, pleural involvement at diagnosis was the important prognostic factor, in addition to WHO histology and Masaoka stage. To prevent pleural recurrence and prolong survival, innovative therapeutic approaches warrant further investigations.",
author = "Kim, {Beom Kyung} and ByoungChul Cho and Choi, {Hye Jin} and Sohn, {Joo Hyuk} and Park, {Moo Suk} and Joon Chang and Kim, {Se Kyu} and Kim, {Dae Joon} and Chung, {Kyung Young} and Lee, {Chang Geol} and Kim, {Joo Hang} and Yoo, {Nae Choon}",
year = "2008",
month = "6",
day = "1",
language = "English",
volume = "19",
pages = "1525--1531",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "6",

}

Kim, BK, Cho, B, Choi, HJ, Sohn, JH, Park, MS, Chang, J, Kim, SK, Kim, DJ, Chung, KY, Lee, CG, Kim, JH & Yoo, NC 2008, 'A single institutional experience of surgically resected thymic epithelial tumors over 10 years - Clinical outcomes and clinicopathologic features', Oncology Reports, vol. 19, no. 6, pp. 1525-1531.

A single institutional experience of surgically resected thymic epithelial tumors over 10 years - Clinical outcomes and clinicopathologic features. / Kim, Beom Kyung; Cho, ByoungChul; Choi, Hye Jin; Sohn, Joo Hyuk; Park, Moo Suk; Chang, Joon; Kim, Se Kyu; Kim, Dae Joon; Chung, Kyung Young; Lee, Chang Geol; Kim, Joo Hang; Yoo, Nae Choon.

In: Oncology Reports, Vol. 19, No. 6, 01.06.2008, p. 1525-1531.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A single institutional experience of surgically resected thymic epithelial tumors over 10 years - Clinical outcomes and clinicopathologic features

AU - Kim, Beom Kyung

AU - Cho, ByoungChul

AU - Choi, Hye Jin

AU - Sohn, Joo Hyuk

AU - Park, Moo Suk

AU - Chang, Joon

AU - Kim, Se Kyu

AU - Kim, Dae Joon

AU - Chung, Kyung Young

AU - Lee, Chang Geol

AU - Kim, Joo Hang

AU - Yoo, Nae Choon

PY - 2008/6/1

Y1 - 2008/6/1

N2 - Thymic epithelial tumors (TETs) consist of a series of neoplasm that differ morphologically and biologically. Due to its rarity and indolent natural history, large-scale prospective trials have been lacking. This study aimed to evaluate long-term clinical outcomes and clinicopathologic features for TET after surgical resection and adjuvant treatments. One hundred patients who received surgery plus adjuvant radiotherapy ± chemotherapy for TET (Masaoka stage II-IVa) from 1995 to 2005 were retrospectively reviewed. Masaoka staging systems were adopted, and pathologic results were classified according to World health organization (WHO) histologic classification. After surgery, 55 patients were treated with radiotherapy alone, while 45 with radiotherapy and chemotherapy. The median radiation dose was 50.4 Gy (45-63 Gy) and six cycles of chemotherapy, consisting of doxorubicin, cisplatin, vincristine and cyclophosphamide, were applied every 3-4 weeks. Distributions according to Masaoka stage were as follows; stage II (58 patients), III (21) and IVa (21). According to WHO histology, there were A (3), AB (7), B1 (7), B2 (31), B3 (31) and C (21). With a median follow-up duration of 65 months (8-143 months), the 5-year overall survival (OS) and disease-free survival (DFS) rates were 75.7% (89.2, 67.9 and 52.1% in stage II, III and IVa, respectively) and 70.3% (83, 62.4 and 33.6% in stage II, III and IVa, respectively). In multivariate analysis, prognostic factors for OS were age, WHO histology, Masaoka stage, and recurrence, while pleural involvement, WHO histology, and Masaoka stage had significant impacts on DFS. Adjuvant chemotherapy did not alter survival outcomes and recurrence patterns. Pleura was the most common recurrence site (15 patients, 53.6%), and significantly associated with pleural recurrence-free survival. In conclusion, pleural involvement at diagnosis was the important prognostic factor, in addition to WHO histology and Masaoka stage. To prevent pleural recurrence and prolong survival, innovative therapeutic approaches warrant further investigations.

AB - Thymic epithelial tumors (TETs) consist of a series of neoplasm that differ morphologically and biologically. Due to its rarity and indolent natural history, large-scale prospective trials have been lacking. This study aimed to evaluate long-term clinical outcomes and clinicopathologic features for TET after surgical resection and adjuvant treatments. One hundred patients who received surgery plus adjuvant radiotherapy ± chemotherapy for TET (Masaoka stage II-IVa) from 1995 to 2005 were retrospectively reviewed. Masaoka staging systems were adopted, and pathologic results were classified according to World health organization (WHO) histologic classification. After surgery, 55 patients were treated with radiotherapy alone, while 45 with radiotherapy and chemotherapy. The median radiation dose was 50.4 Gy (45-63 Gy) and six cycles of chemotherapy, consisting of doxorubicin, cisplatin, vincristine and cyclophosphamide, were applied every 3-4 weeks. Distributions according to Masaoka stage were as follows; stage II (58 patients), III (21) and IVa (21). According to WHO histology, there were A (3), AB (7), B1 (7), B2 (31), B3 (31) and C (21). With a median follow-up duration of 65 months (8-143 months), the 5-year overall survival (OS) and disease-free survival (DFS) rates were 75.7% (89.2, 67.9 and 52.1% in stage II, III and IVa, respectively) and 70.3% (83, 62.4 and 33.6% in stage II, III and IVa, respectively). In multivariate analysis, prognostic factors for OS were age, WHO histology, Masaoka stage, and recurrence, while pleural involvement, WHO histology, and Masaoka stage had significant impacts on DFS. Adjuvant chemotherapy did not alter survival outcomes and recurrence patterns. Pleura was the most common recurrence site (15 patients, 53.6%), and significantly associated with pleural recurrence-free survival. In conclusion, pleural involvement at diagnosis was the important prognostic factor, in addition to WHO histology and Masaoka stage. To prevent pleural recurrence and prolong survival, innovative therapeutic approaches warrant further investigations.

UR - http://www.scopus.com/inward/record.url?scp=48849105358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48849105358&partnerID=8YFLogxK

M3 - Article

C2 - 18497960

AN - SCOPUS:48849105358

VL - 19

SP - 1525

EP - 1531

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 6

ER -